Macular Degeneration Treatment Exeter - Devon

What is macular degeneration?

  

 

The macula is the name given to the centre of the retina (photographic film at the back of the eye). It is responsible for detailed vision (reading, writing, recognising faces) and for colour vision. It is the most sophisticated piece of tissue in the body and works “flat out” from the moment you open your eyes in the morning to the moment you go to sleep. It is responsible for converting the focused image of light striking the retina into electrical impulses that are sent to the brain to give us sight. The cells at the macular that are responsible for changing the light into electricity are called photoreceptors (rods and cones). They work so hard that they need both a very good blood supply called the choroid (to give oxygen and sugar to the cells) and a layer of cells beside them called the Retinal pigment epithelium (RPE) to help them function. The rods and cones need to recycle material in order to function in an efficient manner and the RPE assists in this recycling.

As the macular is working “at full stretch” it is not surprising that with the passage of time it is more prone to the ageing process than other tissues in the body. The light that focuses on the macula and in particular the blue end of the spectrum has high energy and can damage the cells in a variety of ways. The high energy light can produce particles called “free radicals” which damage the cells and the light can also damage the genetic material in the cells called “DNA” that controls the function of the cell. The RPE recycling also becomes less efficient with the passage of time and “waste products” accumulate within the retina called “drusen”

The eye has some defence against this ageing process. Lutein that you get from your diet is present at the macula and helps prevent the high energy blue light from reaching the rods and cones. Anti-oxidant vitamins (such as vitamin C and E) help “mop up” the damaging “free radicals” and this is how vitamin supplements are thought to be beneficial in some patients with macular degeneration. Unfortunately the light damage to the DNA cannot be repaired as the retina (and macula) are part of the central nervous system (part of the brain) and they can only scar and not regenerate or repair easily.

A small number of patients have inherited genes that make them more prone to developing macular degeneration and may develop it at a younger age.

Smoking is a very bad thing for the body for a large number of reasons and this also includes increasing your risk of developing severe macular degeneration.

What are the symptoms of macular degeneration?

 

 

Macular degeneration is the most common cause of loss of vision in patients over the age of 55 in the Western World. Patients complain of a blurred patch in the centre of the vision or sometimes distortion of vision (straight lines looking kinked or uneven).  It must be emphasised however that it is not a blinding condition and does not lead to complete loss of vision. It only involves the central retina (macula) which is an important but only small part of the retina. The side or peripheral retina is unaffected and therefore the side vision or peripheral vision is unaffected. This enables patients to see to navigate around and remain independent. The healthy peripheral retina is also the reason why magnifiers are of benefit to patients with this condition as the image is enlarged onto this.  Symptoms usually develop gradually with dry macular degeneration but are of sudden onset with wet macular degeneration (see below).

Patients with mild macular degeneration are often aware that vision is better in good light and that on waking from sleep in the morning there is often a blurred patch in the centre of the vision that gradually fades. When you wake up in the morning and the lids open, the retina has to start work straight away with the rods and cones converting the light into electricity. In early macular degeneration these cells take longer to “get going” and often need more light to function well and this is the reason for developing these symptoms.

Patients with severe macular degeneration and very poor vision can sometimes develop visual hallucinations called Charles Bonnet syndrome. These may take the form of colours or shapes or more detailed hallucinations such as seeing people who are not there. Almost one third of all input to the brain comes from the eyes so if you have severe macular degeneration there is a large amount of your brain that is not stimulated by the eyes so the brain makes up its own images and hence the development of the hallucinations. They usually settle although can be very disconcerting when they first develop.

There are two types of macular degeneration, dry and wet. This has nothing to do with dryness of the eye or watering of the eye which related to conditions on the surface of the eye (at the front of the eye).

What is dry macular degeneration?

  

 

Dry macular degeneration is a gradual process of wear and tear of the rods and cones and RPE. It therefore produces a gradual blurring of central vision and sometime distortion although this is less frequent.  It can also result in “patchy” central vision with letters and words jumping “in and out” of view. The RPE cells main function is to assist in recycling material from the rods and cones and this recycling process is impaired in dry AMD (age related macular degeneration) and so waste products accumulate called drusen in the retina and can be seen as yellow dots if you look at the optometrists photograph of the retina.

The RPE cells also contain a dark pigment called melanin (similar to the pigment in skin) and this pigment reduces reflections within the eye to help with the focus of light on the retina. The melanin pigment can reduce in amount (resulting in the underlying sclera or white of the eye being visible) or increase in amount with clumps of dark pigment being present in the retina. The optometrists photo of the retina may therefore show yellow spots (drusen) and areas of white (reduced pigment) and areas of dark (increased pigment).

What is the treatment for dry macular degeneration?

 

What is wet macular degeneration?

 

 

Wet macular degeneration usually develops on top of previous dry changes and is less frequent than dry AMD but usually produces more sudden and serious loss of central vision.

Abnormal blood vessels from the choroid (see above) grow forward and into the retina where they can leak causing water logging and thickening of the retina and they can rupture causing haemorrhage and bruising within the retina. If left untreated wet AMD can cause significant loss of central vision. It follows as similar pattern to what happens if you get a cut on the skin. The first thing that happens is haemorrhage and swelling but eventually this settles down and a scar forms. A scar on the skin is a cosmetic blemish but a scar in the centre of your retina results in a permanent blurred patch in the centre of your vision. The treatments that are now available work best if given as soon as possible and are aimed at reducing the swelling and leakage and therefore minimising the size of any subsequent scar that forms.

Patients with macular degeneration can accurately assess the quality of their central vision and monitor the situation with a simple test called an Amsler grid.

Please click here to obtain an Amsler grid you can download and print out.

It consists of a series of lines that make up a grid pattern. In the centre is a dark black spot.  In order to assess your central vision you need to wear your reading glasses or bifocals (try and avoid varifocals) and cover one eye at a time so that each eye is tested separately. You then need to focus on the central black spot. If you have normal sight you should be able to see all the squares clearly and all the lines that make up the squares should appear straight. If some of the lines appear distorted (kinked) or if the squares appear blurred it may suggest a problem at the macula.

Patients with established macular degeneration may already have blurring but it is still important to regularly check the vision as any worsening of the blurring or distortion can be due to progression of the macular degeneration and may require urgent attention. This could be due to dry macular degeneration converting to the wet form or it could be due to patients with wet macular degeneration developing increasing leakage.

Patients with macular degeneration usually require special investigations to accurately assess the macula. The most common and often repeated test is a laser scan of the macula called an OCT (Optical Coherence Tomography). It is very quick and painless and just requires looking at a cross on a screen (there are no bright lights and it can sometimes be performed without having to enlarge the pupil of the eye with drops).

Sometimes a more detailed investigation is needed called an FFA (Fundus Fluorescein Angiography). This involves an injection of iodine dye into a vein in the arm and then taking photographs of the retina as the dye circulates. The gives a very accurate assessment of the circulation at the back of the eye and in particular if there are any abnormal blood vessels present (as they leak the dye) or if there is poor circulation (no dye seen). You sometime feel a little nausea for a few minutes after the injection and your skin (and subsequently your urine) turns yellow for a few hours afterwards.

What is the treatment of wet macular degeneration?

  

 

Treatment for wet macular degeneration improved significantly from 2006 with the development of the drugs Lucentis (Ranibizumab), Avastin (Bevacizumab) and Eylea Aflibercept). Prior to this date the only treatment available for wet AMD were various forms of laser treatment which at best made it less likely for the vision to deteriorate as rapidly as if left untreated but rarely improved the vision. The natural course of wet macular degeneration is that the central vision can deteriorate significantly in the first 6 months following the development of the condition with the greatest deterioration within the first few months. The development of Lucentis and Avastin for the first time resulted in a treatment that could improve the vision in a significant minority of patients and prevent the vision from getting worse in most patients.

These types of drug were first developed to treat cancer patients. In order for a cancer to grow it needs a good blood supply to nourish the cancer cells. The body in health produces a chemical called VEGF (vascular endothelial growth factor) that results in new blood vessel formation and VEGF is also produced by tumour cells to help supply blood to the tumour. The drugs are called anti-VEGF drugs as they stop VEGF from working. This impairs the blood supply to the tumour and can help destroy the tumour.

Wet AMD is obviously not a cancer but it is associated with abnormal blood vessels developing from beneath the retina and growing into the retina with the abnormal blood vessels haemorrhaging and leaking causing bruising and water logging of the retina. This can happen suddenly and hence patients with wet AMD can suddenly develop central blurring and distortion of vision. The sooner wet AMD can be treated the better and Eylea, Lucentis and Avastin all reduce the leakage from these abnormal blood vessels. The aim of treatment is to reduce the leakage as quickly as possible and prevent further leakage to minimise the risk of subsequent scar tissue formation. A scarred macular is no longer able to function and results in permanent loss of central vision.

The ideal situation is that treatment is started within 2 weeks of developing symptoms of wet macular degeneration. Sometimes it can be difficult to know when the disease started especially if the other eye is still maintaining good vision. It is easy to loose a large amount of vision in one eye and not notice a problem if the other eye is still functioning well until you happen to cover the good eye and “suddenly” are aware of the poor vision in the other eye.

The ideal treatment is for the drug to be given as a tablet and only require one dose to be effective. Unfortunately to date no such anti-VEGF drug has been developed. Anti-VEGF drugs if taken in tablet form would be digested by the stomach and made ineffective so they have to be given directly where they are needed. This therefore involves an injection directly into the main eye cavity called the vitreous cavity. This may sound like an unpleasant event but the amount given is very small and is injected though a very fine needle. Most patients do not find the procedure particularly uncomfortable. The injection is usually carried out in a dedicated room as an out-patient procedure. The risk of infection associated with the injection is very low and occurs in 1 in 1,000 injections or less.

Drops are given to numb the surface of the eye and then a solution of weak iodine is placed on the surface of the eye and the skin around the eye also cleaned with iodine (unless you are allergic to iodine when another cleaning solution is used). This may sound old fashioned but iodine is still the best thing for quickly destroying any bugs (bacteria) that are on or around the eye and therefore minimises the risk of infection.

The face is then covered with a light paper drape with a small hole that allows access to the eye that is having the injection. The drape is held away from the face so that you do not feel claustrophobic. A small instrument called a speculum is placed to keep the lids apart and stop you from blinking so sometimes you are aware of a gentle pressure on the lids that can feel a little strange but is not painful. You may be asked to look in a particular direction depending on where the injection is to be given. The injection is over in a second or two and the whole process usually only take a few minutes. After the injection the drape is removed (sometime there is a little pulling on the skin as it is removed) and an antibiotic drop placed on the eye.  Some patients at greater risk of infection may be asked to put antibiotic drops into the eye four times a day for 5 days to minimise the risk of infection. This is performed by first washing your hands then gently pulling the lower lid down and away from the eye and placing a drop in the groove created between the inner aspect of the lower lid and the eye. If you think you have “missed” put another drop in as you cannot “overdose” on these eye drops. There are no other “dos or don’t” after the injection.

Eylea, Lucentis and Avastin usually do require repeated injections in order to maintain the beneficial effect on the vision. They should not be given more frequently than at monthly intervals and most treatments require an initial course of 3 injections or more every month until the vision improves as much as possible then “top up” injections from time to time to try and maintain the improvement in vision or prevent the vision from deteriorating. A small number of patients only need a few injections to produce a good effect but unfortunately a small number of patients also do not respond to treatment or only partially respond.

There is limited evidence to show a slightly increased risk of heart attacks and strokes with these anti-VEGF treatment but the patients requiring this treatment are usually in the age range where such events occur in any case. The injection treatments are therefore very safe but as a precaution I try and avoid giving injections if someone has recently had a heart attack or stroke.

There is also a great deal of media attention about the costs of the drugs and in particular Lucentis and Avastin are made by the same manufacturer. Lucentis has an official licence for use in wet AMD and has been approved by NICE (the body in England that regulates and approves drug use) but is considerable more expensive than Avastin which does not have official approval and is therefore what is termed an “off label” drug. Avastin has however been used extensively worldwide and there are authoritative clinical trials to show it is just as effective as Lucentis in the treatment of wet AMD.

The more recent anti-VEGF drug Eylea (Aflibercept) has been approved by NICE for the treatment of wet AMD and is as effective as Lucentis. There is some evidence to suggest it may be more powerful than Lucentis and therefore may need less frequent top up injections and also be effective in cases that have not responded or only partially responded to Lucentis.

 

What other treatments are needed for macular degeneration?

 

A good light is vital when reading with a diffuse light over your shoulder. Any reading material should ideally be with good contrast (black on white) and large print books are of great benefit if you have mild macular degeneration. There are a variety of low visual aids which are mainly based on the principle of magnification of the image onto the healthy peripheral retina (away from the macula).

The minimum amount of magnification that is needed to help reading is required as the greater the amount of magnification the smaller the number of words or letter you see at one time and this makes it more difficult to see the “flow of words”. The amount of magnification needed however depends on the severity of the macular degeneration with greater magnification needed with more severe disease. Some optometrists (opticians) specialise in low visual aids and sometime there are special “drop in” centres with a large number of low visual aids to try. The low visual aids range from strong reading glasses, through a large range of hand held and stand magnifiers (some with built in illumination) to close circuit television devices when the print to be viewed is magnified onto a computer screen. Most low visual aids are to assist with reading but some telescopic devices are also beneficial for distance vision (such as seeing the number of a bus in the distance).

There are also a large range of other things to help people with visual impairment such as talking books, and various modifications to the house to help you remain independent. It is important to ensure that your local social services are aware of your visual impairment so that you obtain all the benefits available to you and if your sight is sufficiently impaired you should be registered as partially sighted or severely sight impaired. You local eye doctor should perform this for you. Finally in a world where computers are in common use do not forget to enlarge the font size of web pages

Some eye clinics have a liason officer to inform you about the various supporting agencies that are availabe to assist in helping patients with a visual disability.  For more information on this service click here

What about vitamins and macular degeneration?

 

I

f you are a smoker then the single most important thing that you can do is stop smoking. Patients with mild macular degeneration should have a heathy balanced diet with plently of fresh fruit and dark green leaved vegetables. If you have more significant macular degeneration then you should take a vitamin supplement with the AREDS 2 formula containing Vitamin C, Vitamin E, Lutein, Zeaxanthin, Zinc and Copper.

Please click on the video below to see a talk given by Mr Peter Simcock on macular degeneration at the "Top Doctors" seminar organised by the Macular Society and Royal College of Ophthalmologists.